It is currently a matter of physician or patient’s preference how to proceed when a patient flares after unsuccessful treatment with MTX and a first biological (most often anti-TNF as first-line biological therapy in nonsystemic JIA). This evidence concerns the gene TNF and juvenile idiopathic arthritis.